Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| NRG-HN007 | NRG | An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | Adult CIRB - Late Phase Emphasis | Completed | |
| NRG-HN008 | NRG | Phase I Trial with Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients with Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | Adult CIRB - Early Phase Emphasis | Available to Open | |
| NRG-HN009 | NRG | Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-HN010 | NRG | A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-HN011 | NRG | A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-HN014 | NRG | Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response Adapted Treatment versus Standard of Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-LU001 | NRG | Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-LU002 | NRG | Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-LU003 | NRG | A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-LU004 | NRG | Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With MEDI4736 (durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1) | Adult CIRB - Early Phase Emphasis | Available to Open |